Myovant Sciences Ltd plans to raise $60m through the private placement of 15% notes bearing a maturity date of 16 October 2023.

The UK-based biopharmaceutical company plans to use the proceeds towards Phase III trials of its relugolix compound.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Biogen Inc. and Genomics Plc have formed a partnership to develop treatments for multiple sclerosis.

Biogen is a biotechnology company based in the US, while Genomics is an algorithms and software solutions developer based in the UK.

“Biogen Inc. and Genomics Plc have formed a partnership to develop treatments for multiple sclerosis.”

Telix Pharmaceuticals Limited plans to raise A$50.05m ($39.46m) through an initial public offering (IPO) of 77 million shares of its common stock priced at A$0.65 ($0.51) a share.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Australian clinical-stage biotechnology company plans to use the funds to accomplish major product development milestones.

US-based biopharmaceutical company Albireo Pharma, Inc. plans to raise $125m through the issue of common stock or preferred stock, preferred stock or debt securities or any combination of securities.

The company plans to use the funds to advance the development of its A4250 and A3384 product candidates.

German biopharmaceutical company InflaRx GmbH has secured $55m in a series D funding round led by Bain Capital Life Sciences LP.

The company plans to use the funds to carry out clinical Phase IIb trials on its IFX-1 drug candidate, which is indicated for the treatment of chronic inflammatory and auto-immune diseases.